Try our mobile app

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Published: 2023-06-30 13:39:00 ET
<<<  go to ARGX company page

  • First-and-only approved FcRn antagonist for gMG patients by NMPA
  • 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p